Skip to main content
Clinical Trials/NL-OMON55995
NL-OMON55995
Completed
Not Applicable

A study in healthy volunteers to evaluate the effect of repeated LPS skin challenges in a single individual - Effect of repeated local LPS challenges in healthy volunteers

Hoffmann-La Roche0 sites8 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Challenge model development
Sponsor
Hoffmann-La Roche
Enrollment
8
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Healthy male and female subjects, 18 to 45 years of age, inclusive. Healthy
  • status is defined by absence of evidence of any active or chronic disease
  • following a detailed medical and surgical history, a complete physical
  • examination including vital signs, 12\-lead ECG, haematology, blood chemistry,
  • blood serology and urinalysis. In the case of uncertain or questionable
  • results, tests performed during screening may be repeated before enrollment to
  • confirm eligibility or judged to be clinically irrelevant for healthy subjects;
  • 2\. Body mass index (BMI) between 18 and 30 kg/m2 and a minimum weight of 50 kg,
  • 3\. Fitzpatrick skin type I\-III (Caucasian);
  • 4\. Subjects of childbearing potential must use effective contraception for the

Exclusion Criteria

  • 1\. History of pathological scar formation (keloid, hypertrophic scar) or
  • keloids or surgical scars in the target treatment area (lower arm and upper
  • back) that in the opinion of the investigator, would limit or interfere with
  • dosing and/or measurement in the trial;
  • 2\. Have any current and / or recurrent pathologically, clinical significant
  • skin condition at the treatment area (lower arm and upper back, i.e. atopic
  • dermatitis); including tattoos;
  • 3\. Requirement of immunosuppressive or immunomodulatory medication within 30
  • days prior to enrolment or planned to use during the course of the study;
  • 4\. Known immunodeficiency

Outcomes

Primary Outcomes

Not specified

Similar Trials